Takeda Pharmaceutical Company Limited (NYSE: TAK) confirmed that based on the resolution of the Board of Directors meeting held on October 28, 2021, it has decided to finalize the acquisition of its own shares, which was conducted in accordance with the provisions to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act of Japan.
The company has shared the details of shares acquired in April. It has acquired 6,907,500 shares of common stock. The acquisition cost of the shares acquired was incurred around JPY 24,992,962,200. The company has also disclosed that the period of the acquisition was from April 1, 2022, to April 12, 2022. Takeda Pharmaceutical Company Limited also confirmed that it has bought shares from open-market repurchase through a trust bank.
Furthermore, the company has bought 29,376,900 accumulated shares through April 12, 2022, pursuant to the resolution of the Board of Directors’ meeting held on October 28, 2021. The cost of acquisition was JPY 99,965,661,000. As per the details of the resolution at the Board of Directors’ meeting held on October 28, 2021, the company has bought shares of common stock.
Additionally, the total number of shares to be acquired by the company was up to 35 million shares which is equivalent to 2.23% of the total number of shares outstanding excluding treasury shares. As per the details provided by the company, the total acquisition cost of shares to be acquired was around JPY 100 billion. The company has bought shares from November 2, 2021, to April 29, 2022, in open-market repurchase through a trust bank.